Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Army researchers team up to test alternative ways to measure COVID-19 antibody levels

Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.

14 Oct 2020

Research identifies antigen-specific peripheral T follicular helper cells in COVID-19 infected patients

Researchers have found peripheral T follicular helper cell responses to different structural proteins of SARS-CoV-2 and have studied how the response occurs over time.

14 Oct 2020

Study shows SARS-CoV-2 antibodies offer lasting immunity

One of the most significant questions about the novel coronavirus is whether people who are infected are immune from reinfection and, if so, for how long.

14 Oct 2020

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

A new study published on the preprint server bioRxiv in October 2020 shows that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without the rest of the viral components.

14 Oct 2020

NIH launches new study to streamline COVID-19 treatments for larger clinical studies

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials.

14 Oct 2020

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients.

14 Oct 2020

Pre-existing immunity to other coronaviruses may be poor

Brenda M. Westerhuis et al., in a recent medRxiv* preprint paper, investigate the antibody cross-reactivity - to explain the severe disease. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

13 Oct 2020

Mothers transmit passive protection against SARS-CoV-2 to their newborns

A recent study published on the preprint server medRxiv in October 2020 shows that newborns may be protected from acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by antibodies in the mother’s blood that travels through the placenta.

13 Oct 2020

PPE may account for low SARS-CoV-2 seroprevalence in healthcare workers

A recent study published on the preprint server medRxiv in October 2020 shows that among healthcare workers, and especially among first responders, less than 1% and just over 5%, respectively, had antibodies to the virus.

13 Oct 2020

New computational approach improves characterization of cellular diversity

Researchers in the United States have developed a computational method called “weighted-nearest neighbor” (WNN) analysis that can significantly improve the ability to define cellular states across various biological contexts and data types.

13 Oct 2020

Black doctors work to make coronavirus testing more equitable

When the coronavirus arrived in Philadelphia in March, Dr. Ala Stanford hunkered down at home with her husband and kids.

13 Oct 2020

Study offers a better understanding of protective antibodies induced by coronavirus

As vaccine trials progress and public health officials brace for a rise in COVID-19 cases, understanding how the body defends itself from SARS-CoV-2 infection is essential.

13 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses - including several that distinguish it from other COVID-19 vaccine approaches - according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Why blood type O might lower risk for SARS-CoV-2 infection

The author hypothesizes that people with non-O blood groups may have highest contact with the SARS-CoV-2 virus via the formation of in intermediate structure, resulting in possibly higher infection rates and more severe symptoms.

12 Oct 2020

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

A new study by Uppsala University researchers published on the preprint server bioRxiv in October 2020 shows possible links between the angiotensin-converting enzyme 2 (ACE2) host cell receptors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the entry of viral particles into the cell via endocytosis and autophagy.

12 Oct 2020

Understanding the production of memory B cells and immune responses

The current COVID-19 climate has made vaccines, antibodies, and immune responses topics of everyday conversation.

12 Oct 2020

Newly identified coronavirus epitopes induce robust antibody responses

Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.

12 Oct 2020

Scientists develop new type of precise therapeutic vaccine against leukemia

Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

12 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

COVID-19 survivors may have protective antibodies for 4 months

The study, published in the journal Science Immunology, highlights the body's immune response against COVID-19. Also, it offers hope that people who are infected with the SARS-CoV-2 virus will develop lasting protection against reinfection.

11 Oct 2020